Clinicopathological significance of osteopontin in cholangiocarcinoma cases

Asian Pacific Journal of Cancer Prevention

Volumn 17, Issue 1, 2016, Pages 201-205

  Laohaviroj, Marut ^a   Chamgramol, Yaovalux ^a   Pairojkul, Chawalit ^a   Mulvenna, Jason ^b   Sripa, Banchob ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Biomarker; Cholangiocarcinoma; Immunohistochemistry; Osteopontin; Prognostic marker

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

BILE DUCT CARCINOMA; BILE DUCT TUMOR; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; LIVER; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS;

EID: 84957954145     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2016.17.1.201     Document Type: Article

References (28)

1. Bourguignon LY, Zhu H, Shao L, et al (1999). Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton, 43, 269-87.
2. Fedor HL, De Marzo AM (2005). Practical methods for tissue microarray construction. Methods Mol Med, 103, 89-101.
3. Ghouri YA, Mian I, Blechacz B (2015). Cancer review: Cholangiocarcinoma. J Carcinog, 14, 1.
4. Grunnet M, Mau-Sorensen M (2014). Serum tumor markers in bile duct cancer--a review. Biomarkers, 19, 437-43.
5. Hass HG, Nehls O, Jobst J, et al (2008). Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol, 14, 2501-10.
6. Huang Q, Liu L, Liu CH, et al (2012). Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis. Asian Pac J Cancer Prev, 13, 5161-5.
7. Iguchi T, Yamashita N, Aishima S, et al (2009). A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. Oncol, 76, 293-300.
8. Irby RB, McCarthy SM, Yeatman TJ (2004). Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clin Exp Metastasis, 21, 515-23.
9. Juntavee A, Sripa B, Pugkhem A, et al (2005). Expression of sialyl Lewis(a) relates to poor prognosis in cholangiocarcinoma. World J Gastroenterol, 11, 249-54.
10. Khan SA, Taylor-Robinson SD, Toledano MB, et al (2002). Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol, 37, 806-13.
11. Khuntikeo N, Pugkhem A, Titapun A, et al (2014). Surgical management of perihilar cholangiocarcinoma: a Khon Kaen experience. J Hepatobiliary Pancreat Sci, 21, 521-4.
12. Macri A, Versaci A, Lupo G, et al (2009). Role of osteopontin in breast cancer patients. Tumori, 95, 48-52.
13. Nakanuma Y, Sato Y, Harada K, et al (2010). Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol, 2, 419-27.
14. Qiu Y, Hu Y, Zhang ZY, et al (2014). Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients. J Cancer Res Clin Oncol, 140, 2143-56.
15. Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25.
16. Shin HR, Oh JK, Masuyer E, et al (2010). Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia. Asian Pac J Cancer Prev, 11, 1159-66.
17. Silsirivanit A, Araki N, Wongkham C, et al (2011). A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. Cancer, 117, 3393-403.
18. Sirica AE, Dumur CI, Campbell DJ, et al (2009). Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol, 7, 68-78.
19. Sripa B, Bethony JM, Sithithaworn P, et al (2011). Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop, 120, 158-68.
20. Sripa B, Kaewkes S, Intapan PM, et al (2010). Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control. Adv Parasitol, 72, 305-50.
21. Sriputtha S, Khuntikeo N, Promthet S, et al (2013). Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pac J Cancer Prev, 14, 1107-10.
22. Standal T, Borset M, Sundan A (2004). Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol, 26, 179-84.
23. Subraman V, Thiyagarajan M, Malathi N, et al (2015). OPN-Revisited. J Clin Diagn Res, 9, 10-3.
24. Sulpice L, Rayar M, Desille M, et al (2013). Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatol, 58, 1992-2000.
25. Terashi T, Aishima S, Taguchi K, et al (2004). Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int, 24, 38-45.
26. Uttaravichien T, Bhudhisawasdi V, Pairojkul C, et al (1999). Intrahepatic cholangiocarcinoma in Thailand. J Hepatobiliary Pancreat Surg, 6, 128-35.
27. Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al (2010). Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol, 40, 1203-12.
28. Zhao XQ, Dong JH, Zhang WZ, et al (2011). Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. Diagn Pathol, 6, 98.